Chiron deal

CHIR's peptoid and other chemical diversity technologies will be used with Janssen's medicinal chemistry to create new combinatorial libraries that will be screened, along with CHIR's own libraries, against Janssen's biological assays. The goal is to identify new classes of lead compounds that are active against targets such as receptors or enzymes.

Janssen will pay initial license and screening fees to CHIR, plus milestones and research funding over the three-year research period. ...